User profiles for Smith Giri

Smith Giri MD MHS

University of Alabama at Birmingham
Verified email at uabmc.edu
Cited by 4929

[HTML][HTML] Sarcopenia in the older adult with cancer

GR Williams, RF Dunne, S Giri… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
The term sarcopenia, derived from the Greek words sarx for flesh and penia for loss, was first
introduced by Rosenberg 1 in 1989 to describe the loss of muscle mass that accompanies …

[PDF][PDF] RS3PE revisited: a systematic review and meta-analysis of 331 cases

…, D Poudel, T Wasser, A Subedi, S Giri… - Clin Exp …, 2016 - clinexprheumatol.org
Objective Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE)
syndrome is a rare inflammatory arthritis, characterised by symmetrical distal synovitis, pitting …

Rituximab-induced serum sickness: a systematic review

…, R Pathak, AA Donato, S Ghimire, S Giri… - Seminars in arthritis and …, 2015 - Elsevier
Objectives To report a case of rituximab-induced serum sickness (RISS) and perform a
systematic review and characterize RISS in autoimmune diseases and hematological …

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma

…, R Silbermann, B Dhakal, S Bal, S Giri… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …

Low birth weight at term and its determinants in a tertiary hospital of Nepal: a case-control study

SR Sharma, S Giri, U Timalsina, SS Bhandari… - PloS one, 2015 - journals.plos.org
Birth weight of a child is an important indicator of its vulnerability for childhood illness and
chances of survival. A large number of infant deaths can be averted by appropriate …

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

…, R Silbermann, B Dhakal, S Bal, S Giri… - The Lancet …, 2023 - thelancet.com
Background For patients with newly diagnosed multiple myeloma, reaching minimal residual
disease (MRD) negativity after treatment is associated with improved outcomes; however, …

The spectrum of genetic mutations in breast cancer

…, Q Ghori, N Naeem, A Fazil, S Giri… - Asian Pacific Journal …, 2015 - koreascience.kr
Breast cancer is the most common malignancy in women around the world. About one in 12
women in the West develop breast cancer at some point in life. It is estimated that 5%-10% …

Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis

S Giri, A Grimshaw, S Bal, K Godby, P Kharel… - JAMA …, 2020 - jamanetwork.com
Importance The addition of daratumumab to backbone multiple myeloma (MM) regimens is
associated with improved response rates and progression-free survival (PFS). Whether …

Left atrial appendage aneurysm: a systematic review of 82 cases

…, FA Hakim, S Ghimire, S Ghimire, S Giri… - …, 2014 - Wiley Online Library
Background Aneurysm of the left atrial appendage is rare. We sought to systematically
review the published literature on left atrial appendage aneurysm ( LAAA ) to address its …

Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents

S Giri, SF Huntington, R Wang, AM Zeidan… - Blood …, 2020 - ashpublications.org
Chromosome 1 abnormalities (C1As) are common genetic aberrations among patients with
multiple myeloma (MM). We aimed to evaluate the significance of C1As among a …